It has been recently noted that depleting NAD+ by inhibiting nicotinamide phosphoribosyltransferase (NAMPT), a key enzyme in the NAD+ salvage pathway, offers a therapeutical window in AML [28]. The gene discussed is NAMPT; the disease is acute myeloid leukemia.